Application of 3-methyladenine as sensitizer of Polo-like kinase inhibitor in preparation of medicine for treating nasopharynx cancer

The invention provides an application of 3-methyladenine as a sensitizer of a Polo-like kinase inhibitor in preparation of a medicine for treating nasopharynx cancer. The Polo-like kinase inhibitor is preferably a PLK1 (Polo-like kinase 1) inhibitor. And further, the PLK1 inhibitor is GW843682X or BI2536, and the PLK1 inhibitor is GW843682X or BI2536 The invention also provides an application of the combination of the 3-methyladenine and the PLK1 inhibitor in preparation of a medicine for treating nasopharynx cancer. According to the present invention, the detection results show that the killing ability of the PLK1 inhibitor on nasopharyngeal carcinoma cells can be significantly improved by the 3-MA under the condition of no cell proliferation inhibition concentration, the drug onset time is advanced, and according to the experimental results, the 3-MA is the good sensitizer for the PLK1 inhibitor to treat the nasopharyngeal carcinoma, and the 3-MA can activate the CDK1-induced apoptosis signal channel in adv